June 07, 2022 05:33 ET | Source: Research and Markets Research and Markets
Dublin, IRELAND
Dublin, June 07, 2022 (GLOBE NEWSWIRE) — The “Clinical Trials Management System Market Size, Share & Trends Analysis Report by Solution Type (Enterprise, Site), by Delivery Mode (Web & Cloud-based, On-premise), by Component, by End User, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global clinical trials management system market size is anticipated to reach USD 4.72 billion by 2030. The market is expected to expand at a notable CAGR of 13.9% from 2022 to 2030.
The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements. The Clinical Trial Management System offered by SimpleTrials, for instance, includes features such as contact management, calendar & monitoring, project planning, document management & eTMF, contract & payment system, subject tracking, visit report authoring & letter generation, EDC integration, and reporting and business analytics.
The COVID-19 pandemic resulted in several challenges in conducting and operating clinical trials. As per a survey published by Oracle in 2021, 12% reported that clinical trial activity was paused. These respondents represented professionals involved in clinical trials at CROs, medical device companies, and biopharmaceutical companies.
However, the urgency to develop vaccines and other treatment options supported the adoption of emerging technologies. These included video visits, phone visits, remote monitoring, eConsent, and EHR. In fact, about 76% of respondents reported that the pandemic catalyzed their adoption of decentralized clinical trial methods. The trend is projected to continue post-COVID and is expected to propel the demand for CTMS solutions.
Increasing investments by pharmaceutical and biotechnology companies, medical device companies, and CROs coupled with government funding are promoting research activities. This factor is expected to boost demand for clinical trial management systems. According to the estimates of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), global research-based biopharmaceutical industry has spent around USD 179 billion on R&D in 2018.
This number is estimated to reach USD 202 billion by 2022. These investments facilitate the development of new medicines and vaccines to prevent and treat diseases. Some of the popular therapeutic areas for drug development include cancer, immunology, neurology, infectious diseases, and others.
Clinical Trials Management System Market Report Highlights
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Clinical Trials Management System (CTMS) Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Penetration & Growth Prospect Mapping, 2021
3.3 Clinical Trials Management System (CTMS) Market Dynamics
3.3.1 Market driver analysis
3.3.2 Market restraint analysis
3.4 Clinical Trials Management System (CTMS) Market Analysis Tools: Porters
3.5 Clinical Trials Management System (CTMS) Industry Analysis-PEST (Political & Legal, Economic, Social, and Technological)
3.5.1 Political/Legal Landscape
3.5.2 Economic Landscape
3.5.3 Social Landscape
3.5.4 Technology Landscape
Chapter 4. COVID-19 Impact Analysis
4.1 COVID-19 Prevalence Analysis
4.2. Current Impact & Future Scenario
4.3. Impact on Market Players
Chapter 5. Clinical Trials Management System (CTMS) Market : Segment Analysis, by Solution Type, 2017-2030 (USD Million)
5.1 Solution Type Market Share Analysis, 2021 & 2030
5.2 Clinical Trials Management System (CTMS) market, by Solution Type, 2017 to 2030
5.3 Enterprise
5.4 Site
Chapter 6. Clinical Trials Management System (CTMS) Market : Segment Analysis, by Delivery Mode, 2017-2030 (USD Million)
6.1 Delivery Mode Market Share Analysis, 2021 & 2030
6.2 Clinical Trials Management System (CTMS) market, by Delivery Mode, 2017 to 2030
6.3 Web & Cloud-based
6.4 On-premise
Chapter 7. Clinical Trials Management System (CTMS) Market : Segment Analysis, by Component, 2017-2030 (USD Million)
7.1 Component Market Share Analysis, 2021 & 2030
7.2 Clinical Trials Management System (CTMS) Market, by Component, 2017 to 2030
7.3 Software
7.4 Services
Chapter 8. Clinical Trials Management System (CTMS) Market : Segment Analysis, by End User, 2017-2030 (USD Million)
8.1 End User Market Share Analysis, 2021 & 2030
8.2 Clinical Trials Management System (CTMS) Market, by End User, 2017 to 2030
8.3 Pharmaceutical and Biotechnology Firms
8.3.1 Pharmaceutical and Biotechnology Firms market, 2017-2030 (USD Million)
8.4 Medical Device Firms
8.5 Others
Chapter 9. Clinical Trials Management System (CTMS) Market : Regional Market Analysis 2017-2030 (USD Million)
9.1 Definition & Scope
9.2 Regional Movement Analysis, 2021 & 2030
9.3 Regional Market Snapshot
Chapter 10. Clinical Trials Management System (CTMS) Market-Competitive Analysis
10.1 Market Participant Categorization
10.1.1. Company Market Position Analysis
10.1.2. Synergy Analysis: Major Deals & Strategic Alliances
10.1.3. Market Leaders
10.1.4. Innovators
10.2. List of Key Companies
Chapter 11. Clinical Trials Management System (CTMS) Market-Company Profiles
11.1 Company overview
11.2 Financial Performance
11.3 Product benchmarking
11.4 Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/4acwg5
Attachment
Nuxeo has released a new version of its Document Management and Enterprise Platform adding usability and social features.
Driven by community feedback, many of the new features and enhancements improve usability of the application, using standards such as OpenSocial, OAuth, HTML5, WebDAV, and CMIS.
The new WSS connector was contributed by Nuxeo partner Gagnavarslan, an ECM solution provider in Iceland. With this connector, the Nuxeo repository can be mapped as a drive under MS Windows or Mac OS X.
“We are building a range of ECM services based on Nuxeo, and our clients need a smooth desktop integration into an existing Microsoft Windows infrastructure,” said Jónas Sigurðsson, Development Manager at Gagnavarslan in Iceland.
“Our group of developers in Kiev reverse engineered the existing WSS protocol to support Windows 7, Windows XP and the latest MS Office versions directly in Nuxeo EP. We support the open source paradigm and are happy to contribute our work back to the Nuxeo community.”
Other contributions include ongoing enhancements for the OpenSocial integration from customer Leroy Merlin. It now supports the GWT OpenSocial container, making the dashboard faster, and providing more gadgets and layout options.
In addition, the Nuxeo platform is now completely integrated with OpenSocial and fully supports OAuth, allowing for external gadget integration in Nuxeo DM, and the use of Nuxeo DM gadgets in external containers, such as iGoogle. OAuth support ensures control of which services are used and the scope of data shared between applications.
While the GWT container is well equipped to manage dashboards, a new light OpenSocial JavaScript Gadget container offers a quick and easy way to add an OpenSocial gadget to a content template in Nuxeo DM.
Other highlights of Nuxeo EP and DM 5.4.2 include:
HTML 5 Drag’n’Drop. Import single or multiple files via drag’n’drop, without installing a plugin. With a bulk edit feature, metadata can be defined for multiple files on upload.
Local configuration. Configure the document types, themes, and content views that are available for a particular domain or workspace, rather than imposing a universal configuration on the entire repository.
New system properties for the CMIS interface. In addition to the system properties defined in the CMIS specification under the cmis: prefix, Nuxeo EP adds properties under the nuxeo: prefix.
Improved User Interface layout, for a more streamlined access to the user dashboard, document management center, and administration center.
Content Views. Content listings and search results now include filtering options and export options (RSS, ATOM, CSV, Excel, PDF), and can be easily configured with Nuxeo Studio.
Facets. These declarative markers can now be defined on a per-document instance basis instead of only per-document type, giving a more fine-tuned control of search and retrieval operations.
Nuxeo DM 5.4.2 is available with no license charge by downloading it at http://www.nuxeo.com/en/downloads. Download options include an installable application for Windows, Linux or Mac environments, as well as a pre-configured virtual appliance for VMWare or VirtualBox-compatible environments. Nuxeo DM can also be previewed instantly with an online trial version.
Breaking News
Ogun workers suspend strike after four days
Kindly share this story:
Xerox Corporation has re-introduced an Electronic Document Management System in its bid to enhance a smart and efficient post-pandemic workplace.
The EDMS was re-launched in Lagos last week where the company’s teeming customers across public and private establishments supported the idea of having a smart and efficient workplace.
A company statement quoted the General Manager, Sales & Marketing, Xerox Corporation, Mr Femi Abidoye, as saying that the EDMS was re-introduced into Nigeria to meet customers’ expectations and the paradigm shift in the workplace occasioned by the COVID-19 pandemic and global workplace disruptions by professionals from all walks of life.
With the working modalities occasioned by the impact of the COVID-19 pandemic, there have been reductions in workplace activities, especially activities that will ordinarily require the presence of employees at the office.
However, some of the activities around the workplace still revolve around paperwork, some of which include: generating paper documents, photocopying and printing; signing of the paper documents by the parties involved; submission of documents like receipts and invoices by customers and clients; among others.
“As a result, it has been difficult for workplaces to effectively adopt the smart workplace. The Xerox workplace assistants in the intelligent atmosphere with connect key solutions and software on Xerox device is the global solution to all reprographic expectation and documentation need,” the company said in the statement.
Abidoye stressed that COVID-19 has come to stay. As a result, he said a new way of working must be adopted that will not only ensure the safety of workers in the work environment but also ensure productivity of the company with regard to revenue generation and profit-making.
He added, “In order to ensure progress and productivity in these changing times, it is high time organisations embraced Electronic Document Management System, a system that helps ensure that every employee’s documents are always secure and available at their fingertips, granting them secure access, anywhere, any time and on any device.”
According to the statement, EDMS is the sum total of the processes and technologies involved in the creation, management, retrieval, indexing, storage and disposition of documents and records of organisation. In simple terms, it can be defined as digitising of paper documents or conversion of paper documents to electronic documents for easy retrieval, safe storage, management and creation of other documents.
“With Xerox EDMS, you are assured of proper handling of all your document types: be it legacy or current, physical or electronic. We support all file formats, be it text, image, sound or video. It is a solution designed with you in mind, whatever the size of your organization, whatever the nature of business, it can be tailored to fit your current need and grow in scale with you as you progress,” the statement added.
Copyright PUNCH
All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without prior express written permission from PUNCH.
Contact: [email protected]
Tags:
Kindly share this story:
All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without prior express written permission from PUNCH.
Contact: theeditor[at]punchng.com
punchng.com © 1971- 2022 Punch Nigeria Limited